Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Minato A, Furubayashi N, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: furubayashi n. Transl Androl Urol. 2024 Jul 31;13(7):1118-1126. doi: 10.21037/tau-24-53. Epub 2024 Jul 12. Transl Androl Urol. 2024. PMID: 39100842 Free PMC article.
Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: furubayashi n. Clin Genitourin Cancer. 2024 Oct;22(5):102148. doi: 10.1016/j.clgc.2024.102148. Epub 2024 Jul 2. Clin Genitourin Cancer. 2024. PMID: 39033710 Free article.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: furubayashi n. Curr Oncol. 2024 Feb 3;31(2):862-871. doi: 10.3390/curroncol31020064. Curr Oncol. 2024. PMID: 38392058 Free PMC article.
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Masaoka H, Harada M, Tamura S, Kobayashi H, Morihara K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Anticancer Res. 2023 Oct;43(10):4701-4708. doi: 10.21873/anticanres.16666. Anticancer Res. 2023. PMID: 37772560
56 results